Pioneering diagnostics


The discovery and validation of new biomarkers allow patients to receive personalized care, making it possible to develop perfectly targeted and therefore more effective treatments. 

bioMérieux carries out programs designed to discover and/or validate new high medical value biomarkers, particularly in the field of infectious diseases

For critically ill patients

By using the most appropriate technologies, new biomarkers are being validated to improve infectious disease diagnostics and monitoring in acute care and intensive care units. These projects study the patient’s immune response in order to better characterize the different phases of an infectious disease. The goal is to help the physician better understand the disease in order to react sooner. 

In cases of sepsis for example, the discovery of new biomarkers makes it possible to:

  • Identify a possible bacterial infection as quickly as possible;

  • Establish a prognosis to predict disease progression for each patient and determine, as early as possible, the risk of increasing severity;

  • Define patients’ immune profile to target the best treatments;

  • Detect possible organ failure extremely early;

  • Evaluate the risk for immunocompromised patients to contract a healthcare-associated infection (for example, hospitalized patients in intensive care, patients with cancer, etc.).

These biomarkers will contribute to improving medical patient care and thereby optimize healthcare expenses. They will, in particular, help guide the use of antibiotics and combat the resistance of bacteria to these treatments.

The research projects conducted in this field by bioMérieux are strengthened by longstanding collaboration with Hospices Civils of Lyon through two joint research laboratories located at the Edouard Herriot Hospital and the Lyon-Sud Hospital.

For the care for infectious and tropical diseases 

bioMérieux has made a priority of increasing its activities in the field of infectious diseases that affect resource-limited countries. Several projects conducted in Brazil, China, India and Africa aim to validate new biomarkers to improve the diagnosis and monitoring of cosmopolitan diseases such as tuberculosis, or tropical diseases such as malaria, Chagas disease and dengue. These projects receive support through the partnership agreement between Institut Mérieux and Institut Pasteur, which was renewed in 2014.

In addition, bioMérieux has opened a Center of Excellence for Tropical Infectious Diseases within the Christophe Mérieux Laboratory in Rio de Janeiro, Brazil. The center seeks to establish collaborations with experts specialized in infectious diseases impacting Latin America in order to more closely respond to the needs of this region.

In oncology, bioMérieux research teams are working in close collaboration with both Institut Mérieux and oncologists from the Fudan University Cancer Center in Shanghai, China. The objective of their partnership is to identify and validate biomarkers for the early diagnosis and monitoring of certain forms of cancer, and for the prediction of treatment efficacy.

Participation in the ADNA Program

The ADNA program (Advanced Diagnostics for New Therapeutic Approaches), i), initiated in 2006 for a period of 10 years, has been designed to contribute to the development of personalized medicine for the care of infectious diseases, cancer and rare genetic diseases.

Coordinated by Institut Mérieux, the ADNA program brings together four key players

  • bioMérieux, specialized in the field of in vitro diagnostics;

  • Transgene, specialized in the development of therapeutic vaccines;

  • Genethon, specialized in gene therapy;
  • GenoSafe, specialized in immunomonitoring.

Other partners contribute their expertise, including the French Atomic Energy Commission (CEA), the French National Scientific Research Center (CNRS), the University Teaching Hospitals (CHU) of Lyon (Hospices Civils de Lyon), STMicroelectronics and Claude Bernard University in Lyon (UCBL).

Two primary areas of research are developed by bioMérieux within the scope of the ADNA program:

·         The discovery and validation of new high medical value biomarkers;

·         The development of new diagnostic platforms.